A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a)

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02241772

Enrollment

Registered

2014-09-16

Start date

2014-09-30

Completion date

2015-02-28

Last updated

2015-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elevated Lp(a)

Brief summary

A study in males and females with elevated Lp(a) to look at the effects of TA-8995 on Lp(a) levels.

Interventions

DRUGTA-8995

DRUGPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Male and female (of non-child bearing potential) subjects with elevated Lp(a) levels

Exclusion criteria

* Clinically significant medical history * Abnormal laboratory results (other than lipid levels) or vital signs * Receiving any other drug therapy

Design outcomes

Primary

Measure	Time frame
To evaluate the change from baseline in (Lp(a) levels after 12 weeks of treatment with TA-8995.	12 weeks

Secondary

Measure	Time frame
Number of participants with adverse events	12 weeks

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026